Status:
COMPLETED
Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles
Lead Sponsor:
Instituto Valenciano de Infertilidad, IVI VALENCIA
Conditions:
Ovarian Stimulation
Eligibility:
FEMALE
18-37 years
Phase:
PHASE3
Brief Summary
A randomized controlled trial comparing the ongoing pregnancy rate (primary end-point) in 280 patients undergoing IVF/ICSI after stimulation with hp-hMG or rFSH controlled with a GnRH antagonist. Non ...
Eligibility Criteria
Inclusion
- women with good physical and mental health
- aged 18-37 years
- regular menstrual cycles ranging from 25 to 35 days; body mass index (BMI) \< 30 kg/m2
- normal basal serum FSH (≤ 10 IU/L) and E2 (≤ 75 pg/mL) levels determined on the day 3 of the cycle previous to COH
- no uterine (fibroids, adenomyosis, mullerian malformations), ovarian (endometrioma, polycystic ovaries) or adnexa (hydrosalpinx) abnormalities assessed by vaginal ultrasound.
Exclusion
- patients with a history of recurrent pregnancy loss
- any significant systemic disease, endocrine or metabolic disorder
- having concomitant medication interfering with the purposes of the study
- patients who have received any ovulation induction drug within one month before their inclusion in the study.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00669786
Last Update
May 1 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Valenciano de Infertilidad
Valencia, Spain, 46117